Ryan Deschner
Stock Analyst at Raymond James
(4.75)
# 640
Out of 4,690 analysts
70
Total ratings
67.2%
Success rate
37.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintained: Buy | $106 | $67.69 | +56.60% | 13 | Aug 13, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $84 | $34.19 | +145.69% | 7 | Aug 11, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $27 → $40 | $16.79 | +138.24% | 6 | Aug 7, 2026 | |
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $9.16 | +118.34% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $1.82 | +449.45% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $8.10 | +146.91% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $14 → $10 | $2.29 | +336.68% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $32.16 | - | 2 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | n/a | $105.84 | - | 5 | Jun 12, 2026 | |
| ADMA ADMA Biologics | Initiated Coverage: Buy | $21 | $9.34 | +124.84% | 1 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $2.23 | +303.59% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $165 | $97.46 | +69.30% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $12.91 | +78.16% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.89 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $54 → $143 | $149.97 | -4.65% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $12 | $3.81 | n/a | 4 | Aug 5, 2025 |
Liquidia
Aug 13, 2026
Maintained: Buy
Price Target: $106
Current: $67.69
Upside: +56.60%
Vera Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $84
Current: $34.19
Upside: +145.69%
Trevi Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $27 → $40
Current: $16.79
Upside: +138.24%
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $9.16
Upside: +118.34%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $1.82
Upside: +449.45%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $8.10
Upside: +146.91%
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $14 → $10
Current: $2.29
Upside: +336.68%
Viking Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $32.16
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Maintained: Buy
Price Target: n/a
Current: $105.84
Upside: -
ADMA Biologics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $9.34
Upside: +124.84%
May 13, 2026
Maintained: Buy
Price Target: $9
Current: $2.23
Upside: +303.59%
May 7, 2026
Maintained: Buy
Price Target: $110 → $165
Current: $97.46
Upside: +69.30%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $12.91
Upside: +78.16%
Jan 9, 2026
Maintained: Buy
Price Target: n/a
Current: $5.89
Upside: -
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $149.97
Upside: -4.65%
Aug 5, 2025
Maintained: Buy
Price Target: $11 → $12
Current: $3.81
Upside: n/a